NURIX THERAPEUTICS INC. - COMMON STOCK

Nurix Therapeutics Presents Data at the American Association for Cancer Research (AACR) Annual Meeting Highlighting Activity of its BTK Targeted Protein Degraders, NX-2127 and NX-5948, against a Broad Range of BTKi Resistance Mutations

17 Apr 2023 11:30:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results and Provides a Corporate Update

13 Apr 2023 13:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference

11 Apr 2023 13:01:00 By Nasdaq GlobeNewswire

Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479

20 Mar 2023 05:30:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2023 Annual Meeting

14 Mar 2023 13:45:08 By Nasdaq GlobeNewswire

Nurix Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

06 Mar 2023 13:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides a Corporate Update

09 Feb 2023 13:15:00 By Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in Upcoming Investor Conferences

08 Feb 2023 13:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Advances Promising Targeted Protein Modulation Pipeline and Outlines 2023 Strategic Priorities

09 Jan 2023 05:35:39 By Nasdaq GlobeNewswire

Nurix Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

04 Jan 2023 04:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Clearance of Investigational New Drug Application for NX-5948 Supporting Plans to Expand Enrollment to U.S. Clinical Sites

15 Dec 2022 13:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Presents Positive Clinical Results from its Novel BTK Degrader (NX-2127) at the 64th American Society of Hematology (ASH) Annual Meeting

12 Dec 2022 14:30:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Webcast to Review Data from its Phase 1 Clinical Trial of BTK Degrader, NX-2127, Presented at the 64th American Society of Hematology Annual Meeting

07 Dec 2022 13:01:00 By Nasdaq GlobeNewswire

Nurix Announces DeTIL-0255 Scientific Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) and Successful Completion of DeTIL-0255 Phase 1 Safety Run-in

10 Nov 2022 06:00:02 By Nasdaq GlobeNewswire

Nurix Announces Initial NX-1607 Phase 1 Data Presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Demonstrating Targeted CBL-B Inhibition in Patients with Advanced Malignancies

10 Nov 2022 06:00:01 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Presentations at the 64th American Society of Hematology (ASH) Annual Meeting

03 Nov 2022 06:00:01 By Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in Upcoming Investor Conferences

02 Nov 2022 13:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Reports Case Study of Patient with Aggressive Non-Hodgkin’s Lymphoma (NHL) Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation (TPD) Summit

26 Oct 2022 04:00:01 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Presentations at the 5th Annual Targeted Protein Degradation (TPD) Summit

19 Oct 2022 06:00:01 By Nasdaq GlobeNewswire

Nurix Therapeutics Reports Third Quarter Fiscal 2022 Financial Results and Provides a Corporate Update

06 Oct 2022 13:01:00 By Nasdaq GlobeNewswire